We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 21, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , Booking Holdings Inc. (BKNG - Free Report) , Bristol-Myers Squibb Co. (BMY - Free Report) , Equifax Inc. (EFX - Free Report) and First Solar, Inc. (FSLR - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Microsoft, Booking Holdings and Bristol Myers
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Booking Holdings Inc. and Bristol-Myers Squibb Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Microsoft’s shares have outperformed the Zacks Computer - Software industry over the year-to-date period (+57.0% vs. +56.5%). The company is riding on strong growth from Intelligent Cloud and Productivity and Business Processes. Intelligent Cloud revenues have been driven by growth in Azure and other cloud services.
Productivity and Business Processes revenues continue to increase due to strong adoption of Office 365 Commercial solutions. Continued momentum in the small and medium businesses and frontline worker offerings, as well as gain in revenue per user drove top-line growth.
However, More Personal Computing revenues are suffering from continued weakness in Windows and Devices businesses. Steady performance in Talent Solutions aided LinkedIn revenues. However, declining gaming revenues has been a headwind. Increasing spend on Azure enhancements amid stiff competition in the cloud space remains a concern.
Shares of Booking Holdings have outperformed the Zacks Internet - Commerce industry over the year-to-date period (+74.4% vs. +56.5%). The company is benefiting from substantial improvement in its booking trends. Growing demand for travel and solid momentum in booked room nights are driving growth in the gross bookings.
Further, strong global leisure travel demand is a plus. Furthermore, solid momentum across merchant, advertising and other businesses is a major positive. Additionally, strong growth in rental car and airline ticket units is acting as a tailwind. For 2023, the company expects more than 20% year-over-year growth in gross bookings.
Additionally, strengthening alternative accommodation business and flight capabilities are a positive. However, weakness in agency bookings is a headwind. Further, intensifying competition remains a major concern.
Shares of Bristol-Myers Squibb have underperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (-25.0% vs. -15.8%). The company’s performance in 2023 was disappointing. Growth in Opdivo and its new product portfolio (primarily Opdualag, Reblozyl and Zeposia) is being offset by declining revenues due to generic competition for Revlimid and Eliquis (outside the United States).
Nevertheless, the label expansion of Opdivo for first-line lung cancer, bladder cancer and gastric cancer continues to boost sales. The approval of drugs like Opdualag, Reblozyl, Breyanzi and Sotyktu diversifies its revenue base. The impending acquisition of Mirati Therapeutics will strengthen its oncology portfolio.
However, the company now expects its current new-product portfolio to generate $10 billion in revenues by 2026, which was earlier anticipated by 2025. Generic competition for key drugs will remain a headwind.
Other noteworthy reports we are featuring today include Equifax Inc. and First Solar, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar
For Immediate Release
Chicago, IL – December 21, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , Booking Holdings Inc. (BKNG - Free Report) , Bristol-Myers Squibb Co. (BMY - Free Report) , Equifax Inc. (EFX - Free Report) and First Solar, Inc. (FSLR - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Microsoft, Booking Holdings and Bristol Myers
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Booking Holdings Inc. and Bristol-Myers Squibb Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Microsoft’s shares have outperformed the Zacks Computer - Software industry over the year-to-date period (+57.0% vs. +56.5%). The company is riding on strong growth from Intelligent Cloud and Productivity and Business Processes. Intelligent Cloud revenues have been driven by growth in Azure and other cloud services.
Productivity and Business Processes revenues continue to increase due to strong adoption of Office 365 Commercial solutions. Continued momentum in the small and medium businesses and frontline worker offerings, as well as gain in revenue per user drove top-line growth.
However, More Personal Computing revenues are suffering from continued weakness in Windows and Devices businesses. Steady performance in Talent Solutions aided LinkedIn revenues. However, declining gaming revenues has been a headwind. Increasing spend on Azure enhancements amid stiff competition in the cloud space remains a concern.
(You can read the full research report on Microsoft here >>>)
Shares of Booking Holdings have outperformed the Zacks Internet - Commerce industry over the year-to-date period (+74.4% vs. +56.5%). The company is benefiting from substantial improvement in its booking trends. Growing demand for travel and solid momentum in booked room nights are driving growth in the gross bookings.
Further, strong global leisure travel demand is a plus. Furthermore, solid momentum across merchant, advertising and other businesses is a major positive. Additionally, strong growth in rental car and airline ticket units is acting as a tailwind. For 2023, the company expects more than 20% year-over-year growth in gross bookings.
Additionally, strengthening alternative accommodation business and flight capabilities are a positive. However, weakness in agency bookings is a headwind. Further, intensifying competition remains a major concern.
(You can read the full research report on Booking Holdings here >>>)
Shares of Bristol-Myers Squibb have underperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (-25.0% vs. -15.8%). The company’s performance in 2023 was disappointing. Growth in Opdivo and its new product portfolio (primarily Opdualag, Reblozyl and Zeposia) is being offset by declining revenues due to generic competition for Revlimid and Eliquis (outside the United States).
Nevertheless, the label expansion of Opdivo for first-line lung cancer, bladder cancer and gastric cancer continues to boost sales. The approval of drugs like Opdualag, Reblozyl, Breyanzi and Sotyktu diversifies its revenue base. The impending acquisition of Mirati Therapeutics will strengthen its oncology portfolio.
However, the company now expects its current new-product portfolio to generate $10 billion in revenues by 2026, which was earlier anticipated by 2025. Generic competition for key drugs will remain a headwind.
(You can read the full research report on Bristol-Myers Squibb here >>>)
Other noteworthy reports we are featuring today include Equifax Inc. and First Solar, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.